Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Cash from Financing Activities (2016 - 2025)

Intellia Therapeutics (NTLA) has disclosed Cash from Financing Activities for 11 consecutive years, with $2.0 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash from Financing Activities fell 14.67% to $2.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $131.5 million, a 29.21% decrease, with the full-year FY2025 number at $131.5 million, down 29.21% from a year prior.
  • Cash from Financing Activities was $2.0 million for Q4 2025 at Intellia Therapeutics, down from $114.9 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $668.7 million in Q3 2021 to a low of $2.0 million in Q4 2025.
  • A 5-year average of $93.0 million and a median of $24.0 million in 2022 define the central range for Cash from Financing Activities.
  • Biggest YoY gain for Cash from Financing Activities was 111906.7% in 2021; the steepest drop was 99.03% in 2021.
  • Intellia Therapeutics' Cash from Financing Activities stood at $2.3 million in 2021, then soared by 22082.59% to $505.8 million in 2022, then plummeted by 78.95% to $106.5 million in 2023, then plummeted by 97.82% to $2.3 million in 2024, then fell by 14.67% to $2.0 million in 2025.
  • Per Business Quant, the three most recent readings for NTLA's Cash from Financing Activities are $2.0 million (Q4 2025), $114.9 million (Q3 2025), and $14.7 million (Q2 2025).